COVALON TECHNOLOGIES LTD (COV.CA) Stock Fundamental Analysis
Canada - TSX-V:COV - CA22282D3022 - Common Stock
2.18 CAD
-0.01 (-0.46%)
Overall COV gets a fundamental rating of 6 out of 10. We evaluated COV against 21 industry peers in the Biotechnology industry. COV has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. COV is not valued too expensively and it also shows a decent growth rate. With these ratings, COV could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year COV was profitable.
In the past year COV had a positive cash flow from operations.
In multiple years COV reported negative net income over the last 5 years.
In multiple years COV reported negative operating cash flow during the last 5 years.
1.2 Ratios
COV's Return On Assets of 6.56% is amongst the best of the industry. COV outperforms 100.00% of its industry peers.
COV has a Return On Equity of 7.78%. This is amongst the best in the industry. COV outperforms 100.00% of its industry peers.
The Return On Invested Capital of COV (5.16%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 7.78% | ||
| ROIC | 5.16% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of COV (7.00%) is better than 100.00% of its industry peers.
In the last couple of years the Profit Margin of COV has declined.
The Operating Margin of COV (6.60%) is better than 100.00% of its industry peers.
COV's Operating Margin has improved in the last couple of years.
COV has a better Gross Margin (55.68%) than 90.91% of its industry peers.
In the last couple of years the Gross Margin of COV has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.6% | ||
| PM (TTM) | 7% | ||
| GM | 55.68% |
OM growth 3Y233.18%
OM growth 5YN/A
PM growth 3Y-58.52%
PM growth 5YN/A
GM growth 3Y7.01%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for COV has been increased compared to 5 years ago.
2.2 Solvency
COV has an Altman-Z score of 7.16. This indicates that COV is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.16, COV belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
The Debt to FCF ratio of COV is 0.29, which is an excellent value as it means it would take COV, only 0.29 years of fcf income to pay off all of its debts.
COV's Debt to FCF ratio of 0.29 is amongst the best of the industry. COV outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that COV is not too dependend on debt financing.
COV's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. COV outperforms 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.29 | ||
| Altman-Z | 7.16 |
ROIC/WACC0.6
WACC8.55%
2.3 Liquidity
A Current Ratio of 6.57 indicates that COV has no problem at all paying its short term obligations.
COV has a better Current ratio (6.57) than 86.36% of its industry peers.
A Quick Ratio of 4.91 indicates that COV has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.91, COV is doing good in the industry, outperforming 77.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.57 | ||
| Quick Ratio | 4.91 |
3. Growth
3.1 Past
COV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 350.62%, which is quite impressive.
The earnings per share for COV have been decreasing by -50.83% on average. This is quite bad
The Revenue has grown by 13.00% in the past year. This is quite good.
Measured over the past years, COV shows a decrease in Revenue. The Revenue has been decreasing by -1.73% on average per year.
EPS 1Y (TTM)350.62%
EPS 3Y-50.83%
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)13%
Revenue growth 3Y16.8%
Revenue growth 5Y-1.73%
Sales Q2Q%-8.67%
3.2 Future
COV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.98% yearly.
The Revenue is expected to grow by 9.84% on average over the next years. This is quite good.
EPS Next Y-92.31%
EPS Next 2Y-3.92%
EPS Next 3Y9.35%
EPS Next 5Y14.98%
Revenue Next Year7.74%
Revenue Next 2Y11.1%
Revenue Next 3Y10.54%
Revenue Next 5Y9.84%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 27.25, COV can be considered very expensive at the moment.
Based on the Price/Earnings ratio, COV is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.89. COV is around the same levels.
COV is valuated rather expensively with a Price/Forward Earnings ratio of 17.64.
90.91% of the companies in the same industry are more expensive than COV, based on the Price/Forward Earnings ratio.
COV is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.25 | ||
| Fwd PE | 17.64 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, COV is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COV indicates a rather cheap valuation: COV is cheaper than 95.45% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.65 | ||
| EV/EBITDA | 13.73 |
4.3 Compensation for Growth
The decent profitability rating of COV may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.92%
EPS Next 3Y9.35%
5. Dividend
5.1 Amount
No dividends for COV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:COV (10/24/2025, 7:00:00 PM)
2.18
-0.01 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.11%
Ins Owner ChangeN/A
Market Cap59.78M
Revenue(TTM)32.99M
Net Income(TTM)2.31M
Analysts84.44
Price Target3.83 (75.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.91%
Min EPS beat(2)-100%
Max EPS beat(2)94.17%
EPS beat(4)2
Avg EPS beat(4)40.61%
Min EPS beat(4)-100%
Max EPS beat(4)229.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.47%
Min Revenue beat(2)-12.98%
Max Revenue beat(2)-3.96%
Revenue beat(4)1
Avg Revenue beat(4)0.71%
Min Revenue beat(4)-12.98%
Max Revenue beat(4)32.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-88.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.25 | ||
| Fwd PE | 17.64 | ||
| P/S | 1.81 | ||
| P/FCF | 13.65 | ||
| P/OCF | 11.78 | ||
| P/B | 2.01 | ||
| P/tB | 2.11 | ||
| EV/EBITDA | 13.73 |
EPS(TTM)0.08
EY3.67%
EPS(NY)0.12
Fwd EY5.67%
FCF(TTM)0.16
FCFY7.33%
OCF(TTM)0.19
OCFY8.49%
SpS1.2
BVpS1.08
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 7.78% | ||
| ROCE | 7.16% | ||
| ROIC | 5.16% | ||
| ROICexc | 12.73% | ||
| ROICexgc | 14.27% | ||
| OM | 6.6% | ||
| PM (TTM) | 7% | ||
| GM | 55.68% | ||
| FCFM | 13.27% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y199.36%
ROICexgc growth 5YN/A
ROICexc growth 3Y198.52%
ROICexc growth 5YN/A
OM growth 3Y233.18%
OM growth 5YN/A
PM growth 3Y-58.52%
PM growth 5YN/A
GM growth 3Y7.01%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.29 | ||
| Debt/EBITDA | 0.23 | ||
| Cap/Depr | 73.17% | ||
| Cap/Sales | 2.11% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 162.18% | ||
| Profit Quality | 189.61% | ||
| Current Ratio | 6.57 | ||
| Quick Ratio | 4.91 | ||
| Altman-Z | 7.16 |
F-Score5
WACC8.55%
ROIC/WACC0.6
Cap/Depr(3y)94.27%
Cap/Depr(5y)67.08%
Cap/Sales(3y)4.08%
Cap/Sales(5y)2.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)350.62%
EPS 3Y-50.83%
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-92.31%
EPS Next 2Y-3.92%
EPS Next 3Y9.35%
EPS Next 5Y14.98%
Revenue 1Y (TTM)13%
Revenue growth 3Y16.8%
Revenue growth 5Y-1.73%
Sales Q2Q%-8.67%
Revenue Next Year7.74%
Revenue Next 2Y11.1%
Revenue Next 3Y10.54%
Revenue Next 5Y9.84%
EBIT growth 1Y258.74%
EBIT growth 3Y289.15%
EBIT growth 5YN/A
EBIT Next Year-50.79%
EBIT Next 3Y21.1%
EBIT Next 5Y21.26%
FCF growth 1Y225.56%
FCF growth 3Y-51.66%
FCF growth 5YN/A
OCF growth 1Y353.8%
OCF growth 3Y-49.67%
OCF growth 5YN/A
COVALON TECHNOLOGIES LTD / COV.CA FAQ
Can you provide the ChartMill fundamental rating for COVALON TECHNOLOGIES LTD?
ChartMill assigns a fundamental rating of 6 / 10 to COV.CA.
What is the valuation status of COVALON TECHNOLOGIES LTD (COV.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to COVALON TECHNOLOGIES LTD (COV.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for COVALON TECHNOLOGIES LTD?
COVALON TECHNOLOGIES LTD (COV.CA) has a profitability rating of 7 / 10.
What is the earnings growth outlook for COVALON TECHNOLOGIES LTD?
The Earnings per Share (EPS) of COVALON TECHNOLOGIES LTD (COV.CA) is expected to decline by -92.31% in the next year.